Name | NF0BX95A31 |
---|---|
Synonyms | NF0BX95A31 |
Description | CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, inhibits migration and induces cytotoxicity in CXCR4-expressing ovarian cancer cells[1][2]. |
---|---|
Related Catalog | |
Target |
CXCR4 |
In Vitro | CTCE-9908 (0-300 μg/mL; for 10 d) inhibits migration and growth in CXCR4-expressing in ovarian cancer cell lines (IGROV, TOV21G and SKOV3). CTCE-9908 inhibits ovarian cancer cell migration to CXCL12. CTCE-9908 does not cause apoptosis or cellular senescence, but induces multinucleation, G2-M arrest, and abnormal mitosis in ovarian cancer cells. CTCE-9908 deregulates DNA damage checkpoint proteins and spindle assembly checkpoint proteins at G2-M phases of the cell cycle[1]. |
In Vivo | CTCE-9908 (25, 50 and 100 mg/kg; s.c.; 5 days per week for 4.5 weeks) alone slows the rate of primary breast tumor growth, with a 45% inhibition of primary tumor growth at 3.5 weeks of treatment with 50 mg/kg of CTCE-9908 in FVB/N TgN (MMTV-PyMT)634 male mice[2]. |
References |
Molecular Formula | C86H147N27O23 |
---|---|
Molecular Weight | 2041.25 |
Storage condition | -20°C |